Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy-Reference-Cited by-同舟云学术

Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

Published:2017-01-19 Issue:1 Volume:17 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Sereno María,Gutiérrez-Gutiérrez Gerardo,Rubio Juan Moreno,Apellániz-Ruiz María,Sánchez-Barroso Lara,Casado Enrique,Falagan Sandra,López-Gómez Miriam,Merino María,Gómez-Raposo César,Rodriguez-Salas Nuria,Tébar Francisco Zambrana,Rodríguez-Antona Cristina

Funder

Spanish Ministry of Economy and Competiveness

FIS-Carlos III Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-3031-5.pdf

Reference29 articles.

1. Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C, López-Gómez M, Merino- Salvador M, et al. Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol. 2014;89:166–78.

2. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32:997–1005.